Home › NCT04781972
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
Who can join
Ages 6 to 40 · All sexes
Full eligibility criteria
Inclusion Criteria: * right handed Exclusion Criteria: * pregnant or breast feeding * past or current neurological disorder * non-ADHD cause of cognitive impairment * uncontrolled medical disorder * head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma * having an adverse reaction to methylphenidate, or other stimulant medication * having a contraindication to MRI * current smoking
About the study
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
What is being tested
- Methylphenidate (drug)
- Placebo (drug)
Sponsor: Johns Hopkins University · Participants: 30 · Started: Jul 27, 2021
Contact the study team
- Kristin L Bigos, PhD · Phone: 410-614-0453
- Robyn Wiseman, BS · Phone: 304-551-3309
Official record on ClinicalTrials.gov — NCT04781972
Locations in the U.S.
| Maryland | Johns Hopkins School of Medicine, Baltimore |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.